⌘K

Home/Filings/4/0001493152-25-019320

4//SEC Filing

Ally Bridge Group (NY) LLC 4

Accession 0001493152-25-019320

CIK 0001374339other

View on SEC.gov Company Profile

Filed

Oct 23, 8:00 PM ET

Accepted

Oct 24, 4:34 PM ET

Size

13.7 KB

Accession

0001493152-25-019320

Insider Transaction Report

Form 4

Period: 2025-10-22

ProMIS Neurosciences Inc.PMN

Ally Bridge MedAlpha Master Fund L.P.

10% Owner

Transactions

Award
Option (right to buy)
2025-10-22+40,000→ 40,000 total
Exercise: $0.45Exp: 2035-10-22→ Common Shares (40,000 underlying)

ABG Management Ltd.

10% Owner

Transactions

Award
Option (right to buy)
2025-10-22+40,000→ 40,000 total
Exercise: $0.45Exp: 2035-10-22→ Common Shares (40,000 underlying)

Alex Slanix Paul

Director

Transactions

Award
Option (right to buy)
2025-10-22+40,000→ 40,000 total
Exercise: $0.45Exp: 2035-10-22→ Common Shares (40,000 underlying)

10% Owner

Transactions

Award
Option (right to buy)
2025-10-22+40,000→ 40,000 total
Exercise: $0.45Exp: 2035-10-22→ Common Shares (40,000 underlying)

Ally Bridge Group (NY) LLC

10% Owner

Transactions

Award
Option (right to buy)
2025-10-22+40,000→ 40,000 total
Exercise: $0.45Exp: 2035-10-22→ Common Shares (40,000 underlying)

Footnotes (2)

[F1]25% of the shares subject to this option vested on the date of grant and the remaining shares shall vest in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
[F2]This option was granted to Slanix Alex, a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. Dr. Alex holds any equity-based compensation awarded to him for his service as a director of the Issuer for the benefit of Ally Bridge MedAlpha Master Fund L.P. Any proceeds from the sale of shares upon exercise of this award shall be remitted to Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

ProMIS Neurosciences Inc.

CIK 0001374339

Entity typeother

IncorporatedDE

Related Parties

1

filerCIK 0001822947

Filing Metadata

Form type: 4
Filed: Oct 23, 8:00 PM ET
Accepted: Oct 24, 4:34 PM ET
Size: 13.7 KB

View on SEC.gov